- Product Details
Keywords
- Imatinib mesylate price
- Imatinib mesylate CAS 220127-57-1
- Imatinib mesylate supplier in China
Quick Details
- ProName: Imatinib mesylate
- CasNo: 220127-57-1
- Molecular Formula: C30H35N7O4S
- Appearance: Off-white solid
- Application: A tyrosine kinase inhibitor. Highly sp...
- DeliveryTime: 15 days after order confirmed
- PackAge: 25kg/drum;200kg/drum as per your reque...
- Port: Shanghai, Ningbo, Tianjin, etc
- ProductionCapacity: 100 Metric Ton/Month
- Purity: 99%
- Storage: Stored in cool, dry and ventilation pl...
- Transportation: by courier door to door or by sea
- LimitNum: 1 Kilogram
Superiority
Superior quality, moderate price & quick delivery.
Details
Imatinib mesylate Chemical Properties |
mp | 214-224°C |
storage temp. | -20°C Freezer |
CAS DataBase Reference | 220127-57-1(CAS DataBase Reference) |
Safety Information |
Hazardous Substances Data | 220127-57-1(Hazardous Substances Data) |
Imatinib mesylate Usage And Synthesis |
a small-molecule inhibitor |
Imatinib mesylate (also called Gleevec) is a small-molecule inhibitor of the fusion protein Bcr-Abl, the causal agent in chronic myelogenous leukemia. As an inhibitor of PDGFR, imatinib mesylate appears to have utility in the treatment of a variety of dermatological diseases. Imatinib has been reported to be an effective treatment for FIP1L1-PDGFRalpha+ mast cell disease, hypereosinophilic syndrome, and dermatofibrosarcoma protuberans. |
Chemical Properties | Off-White Solid |
Usage | A tyrosine kinase inhibitor. Highly specific for BCR-ABL, the enzyme associated with chronic myelogenous leukemia (CML) and certain forms of acute lymphoblastic leukemia (ALL) |
Usage | Imatinib Mesylate is orally bioavailability mesylate salt of Imatinib, which is a multi-target inhibitor of v-Abl, c-Kit and PDGFR with IC50 of 0.6 μM, 0.1 μM and 0.1 μM, respectively. Imatinib also known as Gleevec, Glivec, CGP-57148B, STI-571 & Imatinib |
Usage | Imatinib Mesylate (STI571) is an orally bioavailability mesylate salt of Imatinib, which is a multi-target inhibitor of v-Abl, c-Kit and PDGFR with IC50 of 0.6 μM, 0.1 μM and 0.1 μM, respectively. |